2096 — Simcere Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- HK$21.51bn
- HK$20.73bn
- CNY6.64bn
- 77
- 28
- 97
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.98 | ||
| PEG Ratio (f) | 0.52 | ||
| EPS Growth (f) | 44.57% | ||
| Dividend Yield (f) | 2.92% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.82 | ||
| Price to Tang. Book | 3.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3 | ||
| EV to EBITDA | 13.22 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.66% | ||
| Return on Equity | 10.26% | ||
| Operating Margin | 12.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 4,508.72 | 4,999.72 | 6,324.08 | 6,607.81 | 6,635.21 | 7,685.48 | 8,782.58 | 5.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -32.68 | +65.05 | -24.99 | -76.29 | +243.09 | +60.37 | +23.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 30th, 2015
- Public Since
- October 27th, 2020
- No. of Employees
- 6,584
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,486,320,618
- Address
- No. 699-18, Xuanwu Road, Xuanwu District, NANJING
- Web
- https://www.simcere.com/
- Phone
- Contact
- Ying Guo
- Auditors
- KPMG
Upcoming Events for 2096
Dividend For 2096.HK - 0.1600 CNY
Half Year 2025 Simcere Pharmaceutical Group Ltd Earnings Release
Similar to 2096
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Simcere Pharmaceutical share price?
As of Today at 23:15 UTC, shares in Simcere Pharmaceutical are trading at HK$8.53. This share price information is delayed by 15 minutes.
How has the Simcere Pharmaceutical share price performed this year?
Shares in Simcere Pharmaceutical last closed at HK$8.53 and the price had moved by +62.79% over the past 365 days. In terms of relative price strength the Simcere Pharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +64.65% over the past year.
What are the analyst and broker recommendations for Simcere Pharmaceutical?
The overall consensus recommendation for Simcere Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Simcere Pharmaceutical dividend yield?
The Simcere Pharmaceutical dividend yield is 2% based on the trailing twelve month period.
Does Simcere Pharmaceutical pay a dividend?
Last year, Simcere Pharmaceutical paid a total dividend of CNY0.16, and it currently has a trailing dividend yield of 2%.Looking ahead, shares in Simcere Pharmaceutical are due to go ex-dividend on 2025-06-18 and the next dividend pay date is 2025-07-14.
When does Simcere Pharmaceutical next pay dividends?
Simcere Pharmaceutical are due to go ex-dividend on 2025-06-18 and the next dividend pay date is 2025-07-14. The historic dividend yield on Simcere Pharmaceutical shares is currently 2%.
How do I buy Simcere Pharmaceutical shares?
To buy shares in Simcere Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Simcere Pharmaceutical?
As of the previous close price of HK$8.53, shares in Simcere Pharmaceutical had a market capitalisation of HK$21.51bn.
Where are Simcere Pharmaceutical shares listed?
Here are the trading details for Simcere Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2096
What kind of share is Simcere Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Simcere Pharmaceutical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Simcere Pharmaceutical share price forecast for 2025?
The analyst consensus target price for shares in Simcere Pharmaceutical is HK$9.53. That is 11.73% above the last closing price of HK$8.53.
Analysts covering Simcere Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY0.47 for the next financial year.
Find out moreWhat is the trend in the Simcere Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Simcere Pharmaceutical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +25.54%.
As of the last closing price of HK$8.53, shares in Simcere Pharmaceutical were trading +26.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Simcere Pharmaceutical PE Ratio?
The Simcere Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 15.98. The shares last closed at HK$8.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Simcere Pharmaceutical?
We do not have data on Simcere Pharmaceutical's directors